WCLC 2025 - Posters & ePosters-P1.07.50 Aumolertinib as Adjuvant Therapy in EGFRm Stage I-III NSCLC With High-Grade Histological Patterns: 3-Year Dfs Rate Updated

P1.07.50 Aumolertinib as Adjuvant Therapy in EGFRm Stage I-III NSCLC With High-Grade Histological Patterns: 3-Year Dfs Rate Updated

Pdf Summary

Summary Not Available

Asset Subtitle

Lijie Wang

Meta Tag

Speaker Lijie Wang

Topic Early-Stage Non-small Cell Lung Cancer